Larry Lasky

Dr. Lasky joined The Column Group in 2014. Dr. Lasky is an expert in biotechnology, a field that he has worked in commercially for over 32 years. In 1981, he was a founding scientist of Genetics Institute (acquired by Wyeth), one of the earliest biotechnology companies. He was subsequently a leading scientist at Genentech for 20 years, where he worked in various disciplines including vaccinology, immunology, stem cell biology, cellular signaling mechanisms, and monoclonal antibody therapy of tumors. He is a co-author on over 135 publications and a co-inventor on 37 issued and pending patents, several of which generate significant licensing royalties. He was a standing member of the Research Review Committee that directed research across all product areas at the company. He also attained the company's highest scientific position, Genentech Fellow, in 1995. As a general partner at Latterell Venture Partners from 2002 to 2007, Larry was instrumental in the founding of Proteolix (acquired by Onyx), Oncomed (nasdaq: OMED), and Cellective Pharmaceuticals (acquired by Medimmune). During his tenure at USVP, he founded or co-founded Intellikine Pharmaceuticals (acquired by Millennium/Takeda), Calithera Pharmaceuticals, Cleave Pharmaceuticals and eFFECTOR pharmaceuticals. Board of Directors: Carmot Therapeutics, eFFECTOR Pharmaceuticals